Transforming cells into cancer fighters - Bristol Myers Squibb

Manufacturing associates execute the transduction step in the cell therapy production process at our facility in Bothell, WA.

Transforming cells into cancer fighters

How CAR T cell therapies are helping patients in need.

Building on our legacy of pioneering transformational science, Bristol Myers Squibb is the first company with two approved chimeric antigen receptor (CAR) T cell therapies in hematologic malignancies with two distinct targets addressing separate blood cancers. Breyanzi (lisocabtagene maraleucel) targets CD19 and treats adults with relapsed or refractory large B-cell lymphoma, and Abecma (idecabtagene vicleucel) targets BCMA and is the first CAR T cell therapy for multiple myeloma approved by the US Food and Drug Administration.

What makes autologous, or patient-derived, CAR T cell therapy so transformational? Through a complex and personalized manufacturing process, these innovative therapies reprogram a patient’s own T cells to fight cancer, and bring the possibility of long-term survival. As a leader in this space, Bristol Myers Squibb continues to explore novel ways to make CAR T and other cell therapies more efficient, scalable and accessible. A new generation of CAR T cell therapies is being studied using the NEX T™ manufacturing process which may produce CAR T cell drug products in a shorter amount of time, with enhanced quality and control.

We are also pursuing early research in allogeneic or “off-the-shelf” CAR T cells that are made from T cells of healthy donors or iPSC (induced pluripotent stem cells) platforms–rather than the patient’s own T cells–and may be delivered to patients in a simpler, faster process.

Building on our broad expertise in cancer research, we are also advancing approaches to CAR T and other cell therapies that may treat solid tumors. These approaches include dual antigen targeting with logic gates to increase tumor specificity, CAR T cells armed with tunable or custom molecules aimed to overcome tumor microenvironment resistance, and discovery of new targets to enable T cell receptor development.

Cell therapies, like all our innovations, are centered on unmet serious needs of our patients. We are committed to advancing the science and putting more patients on the path to a cure.

Patient Story

Man on a mission

Read more >


More Science Stories


A legacy of pioneering advances in cardiovascular disease >
The power of science, the power of AI >
Unleashing the immune system to fight cancer >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at